Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Farmers Insurance
Fish and Richardson
Daiichi Sankyo
Federal Trade Commission
US Department of Justice

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 10,280,209

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,280,209
Title:Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28
Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
Inventor(s): Kaempfer; Raymond (Jerusalem, IL), Shirvan; Anat (Kfar-Saba, IL), Arad; Gila (Mevasseret Zion, IL)
Assignee: ATOX BIO LTD. (Ness Ziona, IL) YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (Jerusalem, IL)
Application Number:15/936,686
Patent Claims:see list of patent claims

Details for Patent 10,280,209

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23 ➤ Sign Up ATOX BIO LTD. (Ness Ziona, IL) YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (Jerusalem, IL) 2039-05-19 RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up ATOX BIO LTD. (Ness Ziona, IL) YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (Jerusalem, IL) 2039-05-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 10,280,209

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2015083173 Jun 11, 2015
United States of America 2016289295 Oct 06, 2016
United States of America 2018215804 Aug 02, 2018
United States of America 9963497 May 08, 2018
Singapore 10201804750X Jul 30, 2018
Singapore 11201604512X Jul 28, 2016
Japan 2017501999 Jan 19, 2017
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
QuintilesIMS
Healthtrust
Citi
UBS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.